It was a great year for Wal-Mart Stores Inc. (NYSE:WMT) in 2016 as the stock was up nearly 13%. Moreover, the stock is off to a decent start this year as it is up approximately 4% year to date.
Over the past few years, the retailer has relished substantial competitive benefits on the back of its enormous scale.Things are gradually changing with the rise of e-commerce sales, however, where Wal-Mart lags behind Amazon (NASDAQ:AMZN).
Wal-Mart, the biggest retailer around the globe, reported its fourth-quarter results on Tuesday. For the quarter, the retailer reported earnings per share of $1.3, surpassing the analyst estimates by one cent. On the other hand, revenue came in at $130.93 billion, missing the consensus by a trivial margin of $290 million. Still, that figure signifies a surge of 1% year over year.
Wal-Mart’s comparable same-store sales in the United States surged 1.8%. Apart from this, one of the most important things to notice is the considerable improvement in e-commerce sales during the quarter. The company reported gross merchandise value growth of 36%, up from 16.8% in the prior quarter. This was partiallly a result of the Jet.com acquisition.
penny stock forum: Piedmont Natural Gas Company Inc.(PNY)
- [By WWW.KIPLINGER.COM]
Duke also recently has expanded on its natural gas efforts, and will add numerous more natural gas customers when its buy-out of Piedmont Natural Gas Company, Inc. (PNY) goes through.
penny stock forum: (SMPQY)
- [By SEEKINGALPHA.COM]
We believe that two main risks currently exist. First, a few days ago, U.S. Department of Justice filed charges in generic drug price-fixing probe. The U.S. Department of Justice accused two former generic pharmaceutical executives of colluding with other generic manufacturers to fix prices – the first criminal charges stemming from a two-year investigation. Companies in the congressional probe have since publicly disclosed that they have received subpoenas, including Mylan NV (NASDAQ:MYL), Allergan (NYSE:AGN), which later sold its generics business to Teva (NASDAQ:TEVA), Lannett (NYSEMKT:LCI), Impax Laboratories (NASDAQ:IPXL), Endo International (NASDAQ:ENDP), Sun Pharmaceutical Industries (OTC:SMPQY), Taro Pharmaceutical Industries Ltd. (NYSE:TARO), and Mayne (OTCPK:MAYNF). This shows that generics are not immune from criticism and price discussions. However, in our opinion, they are safer because they might be the solution to the high-price problem.
- [By SEEKINGALPHA.COM]
The majority owner is Sun Pharma (OTC:SMPQY) (the largest drug business in India). There have been a number of articles that have outlined Sun Pharma and its quest for Taro, but it makes a lot of sense for Sun to want to own all – and not just the majority – of Taro. One big reason is that owning all of Taro means that any investments that Sun makes with Taros $1.2 billion cash hoard will not be diluted by the presence of minority shareholders. Another reason that Sun likely wants Taro is simply because it is very cheap right now. Sun is run by its founder and majority shareholder, Dilip Shanghvi, who is sort of a pharmaceutical value investor who has opportunistically made acquisitions and investments over time, building his firm starting with a loan of $200 in the early 1980s to the multi-billion business it is today.
penny stock forum: (SHF)
- [By Money Morning Staff Reports]
In March 2012, Schiff Nutrition International Inc. (NYSE: SHF) acquired the company for $150 million in cash.
The product is still on the market today, found at most local drug stores. It is advertised now, however, as a nutritional supplement that does not, if taken alone, ward off viruses.
penny stock forum: Big 5 Sporting Goods Corporation(BGFV)
- [By Nicholas Rossolillo]
Dick’s Sporting Goods (NYSE:DKS) and Big 5 Sporting Goods (NASDAQ:BGFV) have both had a great 2016. As far as stock performance goes, Big 5 is the winner this year. But which company is in better shape for the new year?